Evidence map›Paper›PMID 19913031›Full record

ArticleJournal of molecular biology2010

Structure of the flexible amino-terminal domain of prion protein bound to a sulfated glycan.

Lara M Taubner, Ewa A Bienkiewicz, Valérie Copié, Byron Caughey

Abstract read
In one paragraph

Article in Journal of molecular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Unfolded and intermediate states of PrP play a key role in the mechanism of action of an antiprion chaperone.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  5. Prion Protein at the Leading Edge: Its Role in Cell Motility.International journal of molecular sciences · 2020
    Review
  6. Article
  7. N-Terminal Regions of Prion Protein: Functions and Roles in Prion Diseases.International journal of molecular sciences · 2020
    Review
  8. Article
  9. Article
  10. Physiological Functions of the Cellular Prion Protein.Frontiers in molecular biosciences · 2017
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. The N-terminal, polybasic region of PrP(C) dictates the efficiency of prion propagation by binding to PrP(Sc).The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012
    Article
  20. Allosteric function and dysfunction of the prion protein.Cellular and molecular life sciences : CMLS · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Lara M TaubnerRocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA. taubnerl@niaid.nih.gov
Ewa A Bienkiewicz
Valérie Copié
Byron Caughey
National Institute of Allergy and Infectious Diseases · USFlorida State University · USMontana State University · US

Funding

Structures and Activities of Prions and Prion Proteins ZIAAI000580 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CAUGHEY, BYRON · 2009 to 2025
$8.9M
Prion Disease TherapeuticsZIAAI001087 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CAUGHEY, BYRON · 2009 to 2025
$2.5M
SHARED SOLUTION 600 MHZ NMR INSTRUMENTS10RR013878 · NCRR · MONTANA STATE UNIVERSITY (BOZEMAN) · PI COPIE, VALERIE · 1999 to 1999
–
Intramural NIH HHS ZIA AI000580NCRR NIH HHS 1-S10RR13878-01
6 · The paper itself

Abstract

The intrinsically disordered amino-proximal domain of hamster prion protein (PrP) contains four copies of a highly conserved octapeptide sequence, PHGGGWGQ, that is flanked by two polycationic residue clusters. This N-terminal domain mediates the binding of sulfated glycans, which can profoundly influence the conversion of PrP to pathological forms and the progression of prion disease. To investigate the structural consequences of sulfated glycan binding, we performed multidimensional heteronuclear ((1)H, (13)C, (15)N) NMR (nuclear magnetic resonance), circular dichroism (CD), and fluorescence studies on hamster PrP residues 23-106 (PrP 23-106) and fragments thereof when bound to pentosan polysulfate (PPS). While the majority of PrP 23-106 remain disordered upon PPS binding, the octarepeat region adopts a repeating loop-turn structure that we have determined by NMR. The beta-like turns within the repeats are corroborated by CD data demonstrating that these turns are also present, although less pronounced, without PPS. Binding to PPS exposes a hydrophobic surface composed of aligned tryptophan side chains, the spacing and orientation of which are consistent with a self-association or ligand binding site. The unique tryptophan motif was probed by intrinsic tryptophan fluorescence, which displayed enhanced fluorescence of PrP 23-106 when bound to PPS, consistent with the alignment of tryptophan side chains. Chemical-shift mapping identified binding sites on PrP 23-106 for PPS, which include the octarepeat histidine and an N-terminal basic cluster previously linked to sulfated glycan binding. These data may in part explain how sulfated glycans modulate PrP conformational conversions and oligomerizations.

Indexed as

Amino Acid SequenceAnimalsBinding SitesCircular DichroismCricetinaeIn Vitro TechniquesLigandsMacromolecular SubstancesMesocricetusModels, MolecularMolecular Sequence DataNuclear Magnetic Resonance, BiomolecularPentosan Sulfuric PolyesterPrionsProtein BindingProtein ConformationLigandsMacromolecular SubstancesPentosan Sulfuric PolyesterPrionsRecombinant Proteins

Identifiers

PMID19913031
PMCPMC2830820
OpenAlexW2151678605

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.